What a White-Label Peptide Therapy Program Includes (2026)

A white-label peptide therapy program is usually a business-services package, not a transfer of medical authority. It may supply branding, telehealth software, intake workflows, clinician-network coordination, pharmacy or fulfillment coordination, and administrative support. The operator generally owns the brand, marketing decisions, commercial relationships, privacy program, and state-by-state launch work; licensed clinicians retain control over diagnosis, prescribing, records, and patient care.

What is included in a white-label peptide program?

The answer depends on the vendor contract, but a well-defined white-label peptide therapy program commonly has five layers: brand infrastructure, patient workflow technology, clinical-network support, pharmacy coordination, and administrative services. “White label” or “private label” describes commercial packaging. It does not create a separate legal category for medical practice, prescribing, pharmacy operations, or telehealth.

The first step is to request a responsibility matrix rather than relying on a sales description. Every promised feature should be assigned to a specific legal entity and documented in the agreement.

This distinction is central to evaluating white-label telehealth programs. A platform can reduce the number of vendors an operator coordinates without becoming the medical practice or guaranteeing that a proposed model works in every state.

What does the operator own in a private label peptide program?

The operator should negotiate explicit control over the commercial assets that make the business portable. Those assets commonly include the brand name, domain, website configuration, advertising accounts, non-clinical analytics, patient-facing communications, customer-service scripts, and intellectual property created specifically for the business.

The contract should also address patient-record access and export, data retention, subcontractors, incident response, breach notifications, and what happens when the relationship ends. A business that cannot retrieve its operational data or transition patient communications may be locked into a vendor even if the initial launch appears simple.

Ownership is more complicated for medical records. Owning the website or brand does not necessarily mean owning or controlling clinical records. The agreement should separate three categories:

1. 1Business assets: brand materials, software configuration, marketing systems, commercial analytics, and administrative workflows.
2. 2Clinical assets: medical records, clinical protocols, prescribing decisions, clinician supervision, and patient-care decisions.
3. 3Fulfillment records: prescriptions, pharmacy records, labels, shipping records, recall documentation, and adverse-event processes.

California provides a clear example of why this separation matters. The California Medical Board identifies diagnosis, treatment options, referrals, overall patient care, clinician competency decisions, and medical-record ownership as matters that must remain under physician control. California also treats telehealth as a tool of medical practice rather than a separate practice category. A national operator should therefore avoid assuming that its preferred ownership model is acceptable in California.

Operators comparing business structures can also review state ownership rules for medical businesses, but the proposed entity, services, compensation model, and patient locations still require state-specific review.

How do white-label peptide clinics work operationally?

A typical operating workflow has seven stages:

1. 1Brand and scope definition: The operator selects the service concept, target states, patient-facing brand, and permitted marketing language.
2. 2Entity and clinical structure: The operator establishes or contracts with the appropriate business and professional entities, then documents who employs or contracts with clinicians.
3. 3Technology configuration: The vendor configures registration, intake, scheduling, telehealth encounters, consent, payment, documentation, support, and reporting workflows.
4. 4Clinical review: An independently licensed clinician evaluates whether care is appropriate, determines the clinical plan, documents the encounter, and manages follow-up within the clinician’s legal authority.
5. 5Prescription and fulfillment: The parties identify the prescriber, dispensing entity, pharmacy or outsourcing facility, product status, and shipment eligibility.
6. 6Administrative follow-through: Support staff may handle non-clinical questions, billing, scheduling, refunds, and shipping communications without making clinical decisions.
7. 7Monitoring and transition: The operator reviews complaints, privacy incidents, advertising, payment activity, recalls, adverse-event procedures, and vendor performance.

A medical director title does not automatically transfer clinical responsibility to a vendor or authorize a non-clinical company to control a medical practice. The contract should identify who controls clinical hiring, credentialing, supervision, termination, protocols, records, and patient-care decisions.

Who prescribes in a white-label peptide program?

An appropriately licensed clinician prescribes, not the brand or software platform. The clinician must be authorized to practice where the patient is located and must independently make clinical decisions within the applicable professional and state requirements.

A vendor may support recruitment, credentialing workflows, coverage scheduling, templates, or escalation procedures. Those services do not eliminate the operator’s responsibility to verify the clinical entity and the clinicians’ authority for each launch state. They also do not permit the operator to direct diagnosis, treatment options, prescribing, follow-up, or record control.

State examples illustrate the variation:

• California: The Medical Board identifies physician control over diagnosis, treatment options, patient care, clinician competency, and medical records as indicators of control over the medical practice. A non-physician operator generally needs an administrative-services structure supporting a properly organized physician practice rather than ownership of the clinical practice.
• New York: Department of Health materials describe physician-owned professional structures, including professional corporations, professional limited liability companies, physician-only partnerships, and related arrangements. New York guidance also addresses restrictions on an unlicensed corporation providing or arranging professional services. A private label model should be reviewed as a professional-entity and administrative-services arrangement, including compensation provisions.
• Alabama: The Alabama Board of Nursing describes medical oversight for CRNPs and CNMs as concurrent and ongoing physician collaboration, including consultation, patient care, record review, protocols, and outcome indicators. A nominal or distant medical director may not satisfy the actual collaboration and availability expectations.
• Texas: a Texas launch needs its own review of current Texas Medical Board rules, statutes, and the proposed entity and compensation structure.

Rules vary by state. A national program should maintain a state eligibility matrix rather than market itself as automatically available everywhere.

Does a white-label peptide program include a medical director?

It may include medical-director recruitment or contracting support, but the phrase “includes a medical director” is not enough to establish a lawful operating model. The operator should ask which entity contracts with the physician, who controls competency and clinical performance, how coverage works, which states are included, and what collaboration or supervision obligations apply.

The business should also distinguish clinical leadership from administrative support. A vendor can provide quality-assurance workflows or escalation tools while licensed clinicians retain professional judgment. If the compensation arrangement involves a percentage of professional fees, referrals, or other variable payments, obtain state-specific review for fee-splitting, kickback, insurance, and corporate-practice concerns.

What pharmacy and fulfillment services may be included?

A white-label program may coordinate with a pharmacy or outsourcing facility, route orders, facilitate patient communications, or provide shipping-status support. It should not blur who prescribes, who dispenses, who labels the product, or who handles recalls and adverse-event reports.

Before launch, identify:

• The prescriber of record.
• The dispensing pharmacy or outsourcing facility.
• The product’s commercial or compounded status.
• The entity named on the prescription, label, receipt, and patient communications.
• Pharmacy licensure and destination-state shipping eligibility.
• Responsibility for recalls, complaints, adverse events, refunds, and patient questions.

FDA distinguishes section 503A pharmacy compounding from section 503B outsourcing-facility compounding. Section 503A compounding is generally tied to a valid prescription for an identified individual patient. Section 503B outsourcing facilities may compound without prescriptions for identified individual patients but must meet different statutory conditions. Compounded drugs are not FDA-approved.

FDA’s April 1, 2026 communication stated that the tirzepatide shortage had been resolved and reminded compounders that statutory conditions still apply, including limits involving products that are essentially copies of commercially available drugs. FDA’s April 30, 2026 Federal Register notice concerning semaglutide, tirzepatide, and liraglutide in the 503B bulk-substances framework was identified as a proposal, not a final rule. Operators should confirm current status before making formulary or fulfillment claims.

A program may also discuss FDA-approved peptide medications, including medications in the GLP-1 category, when a licensed clinician determines that an approved indication and labeling apply. That does not make a compounded product FDA-approved, equivalent to a branded product, or automatically available through a program.

For additional context on product and prescribing boundaries, see which peptides a telehealth clinic can prescribe under FDA rules.

Is a white-label telehealth platform HIPAA compliant by default?

No. A platform’s marketing label is not a substitute for reviewing data flows, contracts, safeguards, and actual configuration. If a technology vendor creates, receives, maintains, or transmits protected health information for a covered provider, the relationship may require a HIPAA business associate agreement.

The BAA should address permitted uses and disclosures, security safeguards, breach reporting, subcontractors, records access, and return or destruction of information at termination. The operator should also review access controls, encryption, secure transmission, workforce training, risk analysis, incident response, and retention procedures.

Marketing tools need separate scrutiny. Online tracking technologies may disclose health-related information, device identifiers, IP addresses, appointment information, or other data to vendors. The HHS online-tracking guidance includes a June 20, 2024 court-vacatur development affecting part of that guidance, so a generic “HIPAA-compliant” badge is not enough. Current privacy counsel should review pixels, analytics, forms, remarketing, and consent language.

Who owns the advertising and patient experience?

The operator usually owns the commercial relationship with the audience, but that ownership creates advertising responsibilities. Vendor-supplied copy, testimonials, endorsements, and social posts still need review before publication.

FTC guidance states that advertisers may be liable for implied health claims communicated through testimonials, endorsements, websites, social media, and other advertising. Avoid claims implying FDA approval of a compounded product, guaranteed outcomes, safety for everyone, physician endorsement where none exists, or typical results based only on exceptional experiences.

Subscription and membership workflows need payment and cancellation review as well. The FTC’s 2024 click-to-cancel amendments to its Negative Option Rule are not in force: the Eighth Circuit vacated them on July 8, 2025, and the FTC’s March 11, 2026 advance notice of proposed rulemaking is only a proposal. The Restore Online Shoppers’ Confidence Act still requires online sellers of recurring plans to clearly disclose material terms before collecting billing information, obtain express informed consent before charging, and provide a simple way to stop recurring charges.

A buyer’s checklist for evaluating a white-label peptide program

Before signing, ask the vendor to answer these questions in writing:

• Which entity owns the domain, brand, website, and patient-facing content?
• Which entity employs or contracts with clinicians?
• Who controls clinical hiring, credentialing, supervision, and termination?
• Who controls medical records, and can records be exported at termination?
• Who is the prescriber of record?
• Which pharmacy or outsourcing facility dispenses the product?
• Is the product commercially manufactured or compounded?
• Who confirms pharmacy licensure and state shipping eligibility?
• Who handles recalls, complaints, adverse events, refunds, and patient continuity?
• Which party is the HIPAA covered entity?
• Which parties sign BAAs and subcontractor agreements?
• Can the vendor use patient data for its own marketing or remarketing?
• Who approves advertising claims, testimonials, and educational content?
• What are the records, data, and transition obligations when the contract ends?
• Does compensation create fee-splitting, referral, kickback, or insurance concerns?
• Which states are excluded because the model has not been cleared for operation there?

MDLaunchr is the brand behind WhiteLabelClinic.com, one infrastructure option for businesses evaluating the technology, operational, compliance, clinical-network, and fulfillment relationships involved in a telehealth launch. It is not the treating clinician, regulator, pharmacy, law firm, or guarantor that a proposed model will be approved in every jurisdiction. See the peptide therapy program to review how that program is set up, then obtain qualified clinical, legal, privacy, and regulatory review for the proposed business.